Choose Your Country or Region

Trastuzumab (anti-HER2)

Catalog No.A2007 Purity:99.94%

Trastuzumab (anti-human HER2) is a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2, MW:145.53 KD.

Trastuzumab (anti-HER2) Chemical Structure

Click to purchase the isotype control of Trastuzumab (anti-HER2)

Selleck's Trastuzumab (anti-HER2) has been cited by 29 publications

1 Customer Reviews

Purity & Quality Control

Batch: Purity: 99.94% Protein concentration: 4.2mg/ml Endotoxin Level: ＜1EU/mg

99.94

Choose Selective HER2 Inhibitors

Name	Citation	HER2	Others
Canertinib (CI-1033)	46	+++	EGFR
CP-724714	107	++
Sapitinib (AZD8931)	46	++++	ErbB3,EGFR
CUDC-101	22	++	EGFR,HDAC,HDAC1
Mubritinib (TAK 165)	38	++++
AEE788 (NVP-AEE788)	13	++++	EGFR,c-Abl,FLT1
AC480 (BMS-599626)	10	+	HER1,HER4
TAK-285	4	+	EGFR/HER1,HER4,MEK1
Tyrphostin AG 879	3	+	Trk
Poziotinib	33	++++	HER1,HER4
HER2-Inhibitor-1	✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description

Trastuzumab (anti-human HER2) is a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2, MW:145.53 KD.

Features

Human IgG1

Targets

HER2 ^[1]

In Vitro
In vitro	Loss of function of CSK or PTEN confers resistance to both lapatinib and trastuzumab in Human epidermal growth factor receptor 2 (HER2)-amplified gastric cancer (GC) cells.^[1]
Cell Research:	OE19 cells transduced with CSK targeting sgRNAs or PTEN targeting sgRNAs were used for following test. OE19 cells transduced with non-targeting sgRNA as control. a Growth curve of test groups with 0.05 μM lapatinib in combination with indicated dose of trastuzumab for 6 days.

In Vitro

In vitro

Loss of function of CSK or PTEN confers resistance to both lapatinib and trastuzumab in Human epidermal growth factor receptor 2 (HER2)-amplified gastric cancer (GC) cells.^[1]

Cell Research:

OE19 cells transduced with CSK targeting sgRNAs or PTEN targeting sgRNAs were used for following test. OE19 cells transduced with non-targeting sgRNA as control. a Growth curve of test groups with 0.05 μM lapatinib in combination with indicated dose of trastuzumab for 6 days.

In Vivo
In vivo	Trastuzumab exerts antitumor effects in ERBB2-positive AFPGC PDX models, in which statistically significant differences are present in the tumor volume between the group treated with AZD5438 combined with trastuzumab and those treated with AZD5438 or trastuzumab alone in ERBB2 and CCNE1 co-amplified PDX models.^[2]
Animal Research	AnimalModels:Female BALB/c nude mice of ERBB2-positive alpha-fetoprotein producing gastric carcinoma patient-derived xenograft models Dosages:10 mg/kg Administration:i.p.^[2]

In Vivo

In vivo

Trastuzumab exerts antitumor effects in ERBB2-positive AFPGC PDX models, in which statistically significant differences are present in the tumor volume between the group treated with AZD5438 combined with trastuzumab and those treated with AZD5438 or trastuzumab alone in ERBB2 and CCNE1 co-amplified PDX models.^[2]

Animal Research

AnimalModels:Female BALB/c nude mice of ERBB2-positive alpha-fetoprotein producing gastric carcinoma patient-derived xenograft models
Dosages:10 mg/kg
Administration:i.p.^[2]

References
[1] Ning G, et al. BMC Cancer. 2021 Aug 16;21(1):923. [2] Lu J, et al. Nat Commun. 2021 Jun 24;12(1):3946.

References

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	180288-69-1
Isotype	Human IgG1
Source	CHO cells
Formulation	1×PBS, pH6.0
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.

Frequently Asked Questions

Question 1:
How to store the antibody?

Answer:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.